Dr. Hönle AG revised earnings guidance for the year 2021/2022. The Management Board therefore expects sales of EUR 125 million to EUR 130 million and an operating loss (LBIT) of EUR 3 million to EUR 4 million for the Hönle Group in the 2021/2022 financial year. To date, the Executive Board has been expecting sales of between EUR 125 million and EUR 130 million (PY: EUR 115 million) and an operating result (EBIT) of between EUR 9 million and EUR 11 million (PY: EUR 0.3 million).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.35 EUR | 0.00% | -1.53% | +10.57% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.57% | 127M | |
+13.43% | 86.09B | |
+17.10% | 69.35B | |
+18.30% | 36.87B | |
+24.76% | 34.59B | |
+4.68% | 26.91B | |
+10.85% | 28.08B | |
+5.03% | 27.22B | |
+15.85% | 24.95B | |
+19.71% | 25.31B |
- Stock Market
- Equities
- HNL Stock
- News Dr. Hönle AG
- Dr. Hönle AG Revises Earnings Guidance for the Year 2021/2022